OECD says USA needs health care reform

15 December 2008

In spite of improvements, on various measures of health outcomes, the USA appears to rank relatively poorly among Organization for Economic Cooperation and Development countries. Health expenditures, in contrast, are significantly higher than in any other member nation, claims an economic survey of the USA from the OECD.

It notes discrepancies between health outcomes and expenditures in the USA, citing: inequitable access to medical services and subsidized private insurance policies; and inefficiencies in public health insurance. It then suggests two sets of reforms likely to improve the US health care system. The first is a package of reforms to achieve close to universal health insurance coverage. The second relates to payment methods and coverage decisions within the Medicare program to realign incentives and increase the extent of economic evaluation of different medical procedures.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight